CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors
BLA FilingDeramiocelNegative
AI Analysis
Summary
Capricor Therapeutics faces a securities class action lawsuit alleging misstatements regarding Deramiocel clinical data supporting its Biologics License Application, triggering a 64% stock decline.
Outcome Details
Securities class action filed alleging misstatements about clinical data integrity supporting Biologics License Application
Importance:8/10
Sentiment:
-0.95
securities fraudclass action lawsuitclinical data integritystock declineBLADeramiocel
Related Companies
Read the original article
Published by PR Newswire Biotech on August 25, 2026 10:24 AM